



## Clinical trial results:

### A 24-week, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy with 104-Week Open-Label Extension

#### Summary

EudraCT number	2011-004419-22
Trial protocol	DE CZ HU EE SK BG
Global end of trial date	31 July 2014

#### Results information

Result version number	v1 (current)
This version publication date	28 June 2016
First version publication date	07 August 2015

#### Trial information

##### Trial identification

Sponsor protocol code	VX11-509-102
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01590459
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States, 02210-1862
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 September 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	31 July 2014
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of multiple doses of VX-509 when administered for 12 weeks in subjects with active RA on stable MTX therapy. To evaluate the safety and tolerability of multiple doses of VX-509 when administered for 12 weeks in subjects with active RA on stable MTX therapy.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy:

Subjects had been receiving MTX coadministered with folic or folinic acid (at least 5 mg/week) for at least 12 weeks before screening, and had been receiving MTX at a stable dose between 10 mg and 25 mg, orally or subcutaneously administered, per week for at least 8 consecutive weeks.

Evidence for comparator:

There was no active comparator.

Actual start date of recruitment	01 May 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 15
Country: Number of subjects enrolled	Bulgaria: 40
Country: Number of subjects enrolled	Czech Republic: 29
Country: Number of subjects enrolled	Estonia: 16
Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	Hungary: 24
Country: Number of subjects enrolled	Mexico: 41
Country: Number of subjects enrolled	Poland: 39
Country: Number of subjects enrolled	Romania: 3
Country: Number of subjects enrolled	Russian Federation: 21
Country: Number of subjects enrolled	Serbia: 14
Country: Number of subjects enrolled	Slovakia: 1
Country: Number of subjects enrolled	Ukraine: 18
Country: Number of subjects enrolled	United States: 83

Worldwide total number of subjects	358
EEA total number of subjects	166

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	295
From 65 to 84 years	63
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 359 subjects were enrolled, of which 358 subjects received study drug. Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later were eligible to enroll in Escape arm and received 150 mg VX-509 qd or 200 mg VX-509 qd.

### Period 1

Period 1 title	24 Week Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

VX-509-matched placebo up to 24 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509-matched placebo up to 24 weeks.

<b>Arm title</b>	VX-509 100 mg qd
------------------	------------------

Arm description:

VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509 100 mg qd up to 24 weeks.

<b>Arm title</b>	VX- 509 150 mg qd
------------------	-------------------

Arm description:

VX-509 150 mg qd up to 24 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:  
VX-509 150 mg qd up to 24 weeks.

<b>Arm title</b>	VX-509 200 mg qd
------------------	------------------

Arm description:

VX-509 200 mg qd up to 24 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509 200 mg qd up to 24 weeks.

<b>Arm title</b>	VX-509 100 mg bid
------------------	-------------------

Arm description:

VX-509 100 mg twice daily (bid) for up to 24 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509 100 mg bid up to 24 weeks.

<b>Number of subjects in period 1</b>	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd
Started	71	71	72
Completed	58	57	60
Not completed	13	14	12
Physician decision	1	2	-
Death	-	-	-
Did not meet eligibility criteria	1	1	-
Adverse event	6	6	7
Noncompliance with study drug	-	1	-
Unspecified	1	1	-
Lost to follow-up	2	1	-
Refused further dosing for reason other than AE	2	2	5

<b>Number of subjects in period 1</b>	VX-509 200 mg qd	VX-509 100 mg bid
Started	72	72

Completed	59	61
Not completed	13	11
Physician decision	-	-
Death	-	1
Did not meet eligibility criteria	2	-
Adverse event	9	3
Noncompliance with study drug	-	-
Unspecified	-	-
Lost to follow-up	-	1
Refused further dosing for reason other than AE	2	6

## Period 2

Period 2 title	Open Label Extension (OLE)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	VX-509 150 mg qd - OLE

Arm description:

VX-509 150 mg qd up to 104 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509 150 mg qd up to 104 weeks.

<b>Arm title</b>	VX-509 200 mg qd - OLE
------------------	------------------------

Arm description:

VX-509 200 mg qd up to 104 weeks.

Arm type	Experimental
Investigational medicinal product name	VX-509
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

VX-509 200 mg qd up to 104 weeks.

<b>Number of subjects in period 2<sup>[1]</sup></b>	<b>VX-509 150 mg qd - OLE</b>	<b>VX-509 200 mg qd - OLE</b>
Started	47	218
Completed	0	0
Not completed	47	218
Required prohibited medication	-	1
Death	-	1
Did not meet eligibility criteria	-	8
Adverse event	2	8
Study terminated by sponsor	42	188
Unspecified	-	5
Lost to follow-up	1	1
Refused further dosing for reason other than AE	2	6

---

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only subjects who completed 24 weeks of treatment in the Treatment Period and who had at least an ACR20-CRP response were eligible for OLE.

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: VX-509-matched placebo up to 24 weeks.	
Reporting group title	VX-509 100 mg qd
Reporting group description: VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.	
Reporting group title	VX- 509 150 mg qd
Reporting group description: VX-509 150 mg qd up to 24 weeks.	
Reporting group title	VX-509 200 mg qd
Reporting group description: VX-509 200 mg qd up to 24 weeks.	
Reporting group title	VX-509 100 mg bid
Reporting group description: VX-509 100 mg twice daily (bid) for up to 24 weeks.	

Reporting group values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd
Number of subjects	71	71	72
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	52.7	53.5	50.1
standard deviation	± 13.16	± 11.33	± 11.81
Gender categorical			
Units: Subjects			
Female	62	51	58
Male	9	20	14

Reporting group values	VX-509 200 mg qd	VX-509 100 mg bid	Total
Number of subjects	72	72	358
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	53.2	55.7	
standard deviation	± 13.21	± 12.23	-
Gender categorical			
Units: Subjects			
Female	56	62	289
Male	16	10	69



## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: VX-509-matched placebo up to 24 weeks.	
Reporting group title	VX-509 100 mg qd
Reporting group description: VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.	
Reporting group title	VX- 509 150 mg qd
Reporting group description: VX-509 150 mg qd up to 24 weeks.	
Reporting group title	VX-509 200 mg qd
Reporting group description: VX-509 200 mg qd up to 24 weeks.	
Reporting group title	VX-509 100 mg bid
Reporting group description: VX-509 100 mg twice daily (bid) for up to 24 weeks.	
Reporting group title	VX-509 150 mg qd - OLE
Reporting group description: VX-509 150 mg qd up to 104 weeks.	
Reporting group title	VX-509 200 mg qd - OLE
Reporting group description: VX-509 200 mg qd up to 104 weeks.	
Subject analysis set title	VX-509 150 mg qd - Treatment Period, After Escape
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later enrolled in Escape arm and received VX-509 150 mg qd.	
Subject analysis set title	VX-509 200 mg qd - Treatment Period, After Escape
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later were enrolled in Escape arm and received VX-509 200 mg qd.	

### Primary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) C-Reactive Protein (ACR20-CRP) Response at Week 12

End point title	Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) C-Reactive Protein (ACR20-CRP) Response at Week 12
End point description: ACR20-CRP response: greater than equal to ( $\geq$ ) 20% improvement in tender joints count (TJC); $\geq$ 20% improvement in swollen joints count (SJC); and $\geq$ 20% improvement in at least 3 of 5 remaining ACR core measures: subject assessment of pain (assessed on 0-100 mm VAS, higher score = more pain); subject global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); physician global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and CRP levels. Full analysis set included all randomized subjects who received at least 1 dose of study drug.	
End point type	Primary
End point timeframe: Week 12	

<b>End point values</b>	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: percentage of subjects				
number (not applicable)	18.3	46.5	66.7	56.9

<b>End point values</b>	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: percentage of subjects				
number (not applicable)	68.1			

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	VX-509 100 mg qd v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Wald asymptotic test
Parameter estimate	Proportion difference
Point estimate	28.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.5
upper limit	42.8

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	VX- 509 150 mg qd v Placebo
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Wald asymptotic test
Parameter estimate	Proportion difference
Point estimate	48.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	34.2
upper limit	62.5

<b>Statistical analysis title</b>	Statistical Analysis 3
Comparison groups	Placebo v VX-509 200 mg qd
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Wald asymptotic test
Parameter estimate	Proportion difference
Point estimate	38.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.1
upper limit	53.2

<b>Statistical analysis title</b>	Statistical Analysis 4
Comparison groups	VX-509 100 mg bid v Placebo
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Wald asymptotic test
Parameter estimate	Proportion difference
Point estimate	49.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.7
upper limit	63.8

**Primary: Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 12**

End point title	Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 12
-----------------	---

End point description:

DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP milligram per liter [mg/L] and subject general health visual analogue scale score. A score of less than (<2.6) implied remission, <=3.2 implied low disease activity. Full analysis set included all randomized subjects who

received at least 1 dose of study drug.

End point type	Primary
End point timeframe:	
Baseline and Week 12	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	70	70	69
Units: units on scale				
least squares mean (standard error)	-0.76 ( $\pm$ 0.157)	-2.05 ( $\pm$ 0.146)	-2.22 ( $\pm$ 0.14)	-2.48 ( $\pm$ 0.146)

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	71			
Units: units on scale				
least squares mean (standard error)	-2.39 ( $\pm$ 0.142)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	VX-509 100 mg qd v Placebo
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed effect model
Parameter estimate	Treatment difference
Point estimate	-1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.68
upper limit	-0.88

Statistical analysis title	Statistical Analysis 2
Comparison groups	VX- 509 150 mg qd v Placebo

Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed effect model
Parameter estimate	Treatment difference
Point estimate	-1.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.85
upper limit	-1.06

<b>Statistical analysis title</b>	Statistical Analysis 3
Comparison groups	VX-509 200 mg qd v Placebo
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed effect model
Parameter estimate	Treatment difference
Point estimate	-1.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.11
upper limit	-1.32

<b>Statistical analysis title</b>	Statistical Analysis 4
Comparison groups	VX-509 100 mg bid v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed effect model
Parameter estimate	Treatment difference
Point estimate	-1.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.01
upper limit	-1.23

## Primary: Safety and Tolerability as Assessed by Adverse Events (AEs) Through Week

End point title	Safety and Tolerability as Assessed by Adverse Events (AEs) Through Week 24 <sup>[1]</sup>
-----------------	--

End point description:

AE: any untoward medical occurrence in a subject during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE included serious as well as non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Safety set included all randomized subjects who received at least 1 dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Through Week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not planned for safety endpoint.

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: number of subjects				
number (not applicable)				
Subjects with AEs	30	37	44	49
Subjects with SAEs	4	3	6	5

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: number of subjects				
number (not applicable)				
Subjects with AEs	42	11	36	
Subjects with SAEs	7	1	5	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects Achieving ACR-CRP Responses

End point title	Percentage of Subjects Achieving ACR-CRP Responses
-----------------	--

End point description:

ACR20-CRP at Week 24 and ACR50/70-CRP at Week 12 and 24 are reported. ACR20-CRP is defined in

first primary endpoint. ACR50/70-CRP response:  $\geq 50\%/70\%$  improvement in TJC;  $\geq 50\%/70\%$  improvement in SJC; and  $\geq 50\%/70\%$  improvement in at least 3 of 5 remaining ACR core measures: subject assessment of pain (assessed on 0-100 mm VAS, higher score = more pain); subject global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); physician global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); self-assessed disability (disability index of the HAQ); and CRP levels. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
End point timeframe:	
Week 12 and 24	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: percentage of subjects				
number (not applicable)				
Week 24: ACR20 CRP	16.9	60.6	61.1	61.1
Week 12: ACR50 CRP	7	22.5	38.9	34.7
Week 12: ACR70 CRP	2.8	9.9	11.1	9.7
Week 24: ACR50 CRP	7	38	38.9	40.3
Week 24: ACR70 CRP	2.8	16.9	18.1	15.3

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: percentage of subjects				
number (not applicable)				
Week 24: ACR20 CRP	62.5			
Week 12: ACR50 CRP	38.9			
Week 12: ACR70 CRP	22.2			
Week 24: ACR50 CRP	47.2			
Week 24: ACR70 CRP	25			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects who Achieved a Moderate or Good Response with European League Against Rheumatism (EULAR) Response at Week 12 and 24

End point title	Percentage of Subjects who Achieved a Moderate or Good Response with European League Against Rheumatism (EULAR) Response at Week 12 and 24
-----------------	--

End point description:

DAS28-4 (CRP) EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached.

Good responders: change from baseline >1.2 with DAS28-4 (CRP) =< 3.2; moderate responders: change from baseline >1.2 with DAS28-4 (CRP) >3.2 or change from baseline >0.6 to =<1.2 with DAS28-4 (CRP) =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28-4 CPR >5.1. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
End point timeframe:	
Week 12 and 24	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: percentage of subjects				
number (not applicable)				
Week 12	25.4	57.7	69.4	65.3
Week 24	19.7	56.3	62.5	61.1

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: percentage of subjects				
number (not applicable)				
Week 12	68.1			
Week 24	61.1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with DAS28-4 (CRP) Remission at Week 12 and 24

End point title	Percentage of Subjects with DAS28-4 (CRP) Remission at Week 12 and 24
-----------------	---

End point description:

DAS28-4 (CRP) is defined in second primary endpoint. DAS28-4 (CRP) score <2.6 was considered remission. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
End point timeframe:	
Week 12 and 24	



End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: percentage of subjects				
number (not applicable)				
Week 12	2.8	16.9	29.2	22.2
Week 24	5.6	21.1	29.2	27.8

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: percentage of subjects				
number (not applicable)				
Week 12	30.6			
Week 24	31.9			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in DAS28-4 (CRP) at Week 24

End point title	Change from Baseline in DAS28-4 (CRP) at Week 24
End point description:	
DAS28-4 (CRP) is defined in second primary endpoint. Full analysis set included all randomized subjects who received at least 1 dose of study drug.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	70	70	69
Units: units on scale				
least squares mean (standard error)	-1.51 (± 0.215)	-2.35 (± 0.158)	-2.35 (± 0.148)	-2.68 (± 0.156)

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	71			

Units: units on scale				
least squares mean (standard error)	-2.86 (± 0.154)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects who Achieved Remission as Defined by the ACR/EULAR Criteria

End point title	Percentage of Subjects who Achieved Remission as Defined by the ACR/EULAR Criteria
End point description: Subject was considered to be in remission when either scores on the tender joint count, swollen joint count, CRP (in mg/dL), and subject global assessment (0 to 10 scale) were all ≤1; or score on the Simplified Disease Activity Index (SDAI) was ≤3.3. Full analysis set included all randomized subjects who received at least 1 dose of study drug.	
End point type	Secondary
End point timeframe: Week 12 and 24	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: percentage of subjects				
number (not applicable)				
Week 12	0	5.6	5.6	6.9
Week 24	0	9.9	11.1	6.9

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: percentage of subjects				
number (not applicable)				
Week 12	6.9			
Week 24	15.3			

### Statistical analyses

No statistical analyses for this end point

**Secondary: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12 and Week 24**

End point title	Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12 and Week 24
-----------------	--

End point description:

The HAQ-DI is a self-completed subject questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Domain score = total score of individual questions divided by total number of questions. HAQ-DI total score = total of domain scores divided by number of domains, range: 0 (best) to 3 (worst). Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
least squares mean (standard error)				
Week 12	-0.28 (± 0.071)	-0.49 (± 0.068)	-0.58 (± 0.065)	-0.63 (± 0.068)
Week 24	-0.6 (± 0.09)	-0.62 (± 0.07)	-0.65 (± 0.067)	-0.79 (± 0.069)

End point values	VX-509 100 mg bid			
Subject group type	Reporting group			
Number of subjects analysed	72			
Units: units on scale				
least squares mean (standard error)				
Week 12	-0.62 (± 0.066)			
Week 24	-0.75 (± 0.068)			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change from Baseline in Subject Global Assessment of Disease Activity at Week 12 and 24**

End point title	Change from Baseline in Subject Global Assessment of Disease Activity at Week 12 and 24
-----------------	---

End point description:

Subject assessed overall arthritis activity on an 11-point scale ranging from 0 (none) to 10 (extreme).

Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
End point timeframe:	
Baseline, Week 12 and Week 24	

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-1.3 (± 2.31)	-2.6 (± 2.62)	-2.8 (± 2.13)	-2.8 (± 2.37)
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-1.9 (± 3.2)	-3.9 (± 2.19)	-2.9 (± 2.46)	-3.7 (± 2.3)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-3.6 (± 2.66)	-2.2 (± 1.8)	-2.3 (± 1.88)	
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-4.5 (± 2.34)	-3.4 (± 2.55)	-3.1 (± 2.8)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Subject Assessment of Pain Visual Analog Scale (VAS) Score at Week 12 and 24

End point title	Change from Baseline in Subject Assessment of Pain Visual Analog Scale (VAS) Score at Week 12 and 24
End point description:	
Subjects indicated the amount of pain they were experiencing using a 100 millimeter (mm) VAS. VAS range: 0 mm (no pain) to 100 mm (pain as bad as it could be). Full analysis set included all randomized subjects who received at least 1 dose of study drug.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12 and 24	

<b>End point values</b>	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-10.1 (± 22.68)	-22.4 (± 26.57)	-24.4 (± 22.51)	-25.5 (± 25.17)
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-19.3 (± 32.17)	-34.8 (± 22.3)	-25.8 (± 26.78)	-34.8 (± 25.38)

<b>End point values</b>	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-31.6 (± 25.02)	-22.5 (± 18.67)	-22.1 (± 18.54)	
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-41.4 (± 23.09)	-31.8 (± 24.99)	-30 (± 22.04)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Subject General Health VAS Score at Week 12 and 24

End point title	Change from Baseline in Subject General Health VAS Score at Week 12 and 24
-----------------	--

End point description:

Subjects rated their health using a 100 mm VAS. VAS range: 0 mm (very well) to 100 mm (extremely bad). Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 18, 45)	-7.3 (± 24.3)	-18.6 (± 23.69)	-19.7 (± 24.69)	-21.2 (± 23.3)
Week 24 (n= 17, 44, 53, 47, 49, 26, 55)	-18.2 (± 33.1)	-24.2 (± 24.2)	-19 (± 23.89)	-28.9 (± 23.1)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 18, 45)	-23.8 (± 26.17)	-21.6 (± 26.95)	-22.6 (± 24.48)	
Week 24 (n= 17, 44, 53, 47, 49, 26, 55)	-35.4 (± 25.41)	-29.3 (± 27.33)	-31.8 (± 24.15)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in the Physical Component and Mental Component of the Short Form-36 (SF-36) at Week 12 and 24

End point title	Change from Baseline in the Physical Component and Mental Component of the Short Form-36 (SF-36) at Week 12 and 24
-----------------	--

End point description:

SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores (CS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Change from baseline in physical (PC) and mental component (MC) norm based scores (NBS) are reported. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 – MC NBS (n= 39, 52, 59, 52, 58, 15, 42)	2.056 (± 10.7207)	4.525 (± 11.5951)	5.022 (± 9.3893)	6.039 (± 10.8664)
Week 12 – PC NBS (n= 39, 51, 59, 52, 58, 15, 42)	5.508 (± 7.7841)	6.116 (± 5.8375)	7.447 (± 7.2476)	8.642 (± 6.9517)
Week 24 – MC NBS (n= 17, 44, 53, 47, 50, 27, 55)	7.429 (± 12.3269)	4.641 (± 11.3092)	5.347 (± 10.068)	8.479 (± 9.9463)
Week 24 – PC NBS (n= 17, 43, 53, 47, 50, 27, 55)	10.411 (± 8.2095)	8.12 (± 6.9881)	9.066 (± 8.8524)	11.444 (± 7.9637)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 – MC NBS (n= 39, 52, 59, 52, 58, 15, 42)	5.886 (± 10.7011)	1.76 (± 10.5982)	3.558 (± 10.047)	
Week 12 – PC NBS (n= 39, 51, 59, 52, 58, 15, 42)	8.936 (± 8.4752)	5.482 (± 5.4057)	4.383 (± 5.4056)	
Week 24 – MC NBS (n= 17, 44, 53, 47, 50, 27, 55)	7.705 (± 11.9373)	4.669 (± 9.4316)	4.157 (± 8.4898)	
Week 24 – PC NBS (n= 17, 43, 53, 47, 50, 27, 55)	11.168 (± 7.3012)	8.961 (± 8.5279)	6.977 (± 7.4528)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) Score at Week 12 and 24

End point title	Change from Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) Score at Week 12 and 24
-----------------	--

End point description:

The RAQoL questionnaire is a 30-item self-administered measure that was specifically designed to assess the health-related quality of life of people with RA. Each item is in the form a simple statement to which subjects respond "Yes" or "No." "Yes" scores 1 and "No" scores 0. The overall score is the sum of the individual item scores, ranging from 0 to 30, with a lower score indicating better quality of life. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-3.05 (± 7.247)	-5.37 (± 8.049)	-5.11 (± 5.272)	-6.67 (± 6.597)
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-5.35 (± 9.219)	-7.34 (± 9.514)	-6.16 (± 6.404)	-8.76 (± 7.053)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	-6.59 (± 7.923)	-2.37 (± 6.066)	-2.89 (± 7.101)	
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	-7.98 (± 7.249)	-4.78 (± 7.49)	-4.65 (± 6.692)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Subject-Assessed Duration of Morning Stiffness at Week 12 and 24

End point title	Change from Baseline in Subject-Assessed Duration of Morning Stiffness at Week 12 and 24
-----------------	--

End point description:

Morning stiffness was defined as stiffness in and around the joints, assessed by subject. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24



<b>End point values</b>	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: minutes				
arithmetic mean (standard deviation)				
Week 12 (38, 51, 59, 52, 57, 19, 44)	-37 (± 49.44)	-64.1 (± 63.19)	-60.4 (± 69.91)	-61.3 (± 49.71)
Week 24 (16, 43, 52, 47, 50, 27, 54)	-59.7 (± 68.03)	-71.5 (± 52.66)	-72.3 (± 71.22)	-67.1 (± 52.35)

<b>End point values</b>	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: minutes				
arithmetic mean (standard deviation)				
Week 12 (38, 51, 59, 52, 57, 19, 44)	-73 (± 63.25)	-35.3 (± 88.65)	-39.9 (± 60.21)	
Week 24 (16, 43, 52, 47, 50, 27, 54)	-79.1 (± 74.01)	-72.4 (± 52.75)	-67.2 (± 71.91)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Functional Assessment of Chronic illness Therapy-Fatigue (FACIT-F) Scale Score at Week 12 and 24

End point title	Change from Baseline in Functional Assessment of Chronic illness Therapy-Fatigue (FACIT-F) Scale Score at Week 12 and 24
-----------------	--

End point description:

The FACIT-F is a 13-item self-administered tool that measures an individual's level of fatigue during usual daily activities over the past week. The level of fatigue is measured on a five-point Likert-type scale from 4 = not at all fatigued to 0 = very much fatigued; some questions are reverse-scored. The FACIT-Fatigue score is the sum of the individual item scores multiplied by 13 and divided by the number of items answered; the range is 0 to 52, with higher scores indicating better quality of life. Full analysis set included all randomized subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	5.13 (± 10.603)	5.76 (± 10.845)	6.36 (± 7.998)	8.49 (± 10.299)
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	9.24 (± 12.77)	8.45 (± 11.487)	6.83 (± 9.468)	12.23 (± 11.309)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	10.39 (± 10.994)	3.11 (± 8.333)	3.38 (± 8.778)	
Week 24 (n= 17, 44, 53, 47, 50, 27, 55)	12.69 (± 10.017)	7.3 (± 11.207)	6.04 (± 8.604)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Medical Outcomes Study-Sleep Module questionnaire (MOS-Sleep) Overall 9-Item Index Score at Week 12 and 24

End point title	Change from Baseline in Medical Outcomes Study-Sleep Module questionnaire (MOS-Sleep) Overall 9-Item Index Score at Week 12 and 24
-----------------	--

End point description:

The MOS Sleep Scale is a subject-rated questionnaire consisting of 12 items that assess the key constructs of sleep; assesses sleep for the 4 weeks prior to evaluation. The MOS Overall Sleep Problems Index is a 9-item sub-scale; norm based scores (NBS) range from 0 to 100, lower scores indicate fewer sleep problems. Full analysis set included all randomized subjects who received at least 1 dose of study drug

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 and 24

End point values	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (39, 51, 57, 51, 55, 19, 45)	5.541 (± 10.2069)	6.162 (± 8.1018)	6.107 (± 7.0598)	5.752 (± 8.5562)
Week 24 (17, 44, 50, 44, 49, 27, 55)	9.906 (± 13.1697)	6.953 (± 8.6609)	7.102 (± 6.4437)	8.325 (± 9.4486)

End point values	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (39, 51, 57, 51, 55, 19, 45)	7.834 (± 7.6625)	2.143 (± 8.44)	5.862 (± 7.4288)	
Week 24 (17, 44, 50, 44, 49, 27, 55)	7.303 (± 7.8772)	4.471 (± 7.3857)	5.281 (± 7.0525)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in the EuroQol (EQ-5D) Total Score at Week 12 and 24

End point title	Change from Baseline in the EuroQol (EQ-5D) Total Score at Week 12 and 24
End point description:	
The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. Full analysis set included all randomized subjects who received at least 1 dose of study drug	
End point type	Secondary
End point timeframe:	
Baseline, Week 12 and 24	

<b>End point values</b>	Placebo	VX-509 100 mg qd	VX- 509 150 mg qd	VX-509 200 mg qd
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	71	71	72	72
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	0.1413 (± 0.2555)	0.1313 (± 0.19425)	0.1146 (± 0.16821)	0.1767 (± 0.19794)
Week 24 (n= 17, 44, 52, 47, 50, 27, 55)	0.1875 (± 0.27244)	0.1797 (± 0.24581)	0.136 (± 0.18494)	0.2294 (± 0.20718)

<b>End point values</b>	VX-509 100 mg bid	VX-509 150 mg qd - Treatment Period, After Escape	VX-509 200 mg qd - Treatment Period, After Escape	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	72	29	64	
Units: units on scale				
arithmetic mean (standard deviation)				
Week 12 (n= 39, 52, 59, 52, 58, 19, 45)	0.1621 (± 0.18571)	0.0634 (± 0.15886)	0.0785 (± 0.17708)	
Week 24 (n= 17, 44, 52, 47, 50, 27, 55)	0.1974 (± 0.20298)	0.1305 (± 0.19656)	0.1093 (± 0.17024)	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

First dose of study drug up to 28 days after last dose of study drug

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

### Reporting groups

Reporting group title	Placebo - Before Escape
-----------------------	-------------------------

Reporting group description:

VX-509-matched placebo qd up to 24 weeks.

Reporting group title	VX-509 100 mg qd - Before Escape
-----------------------	----------------------------------

Reporting group description:

VX-509 100 mg qd up to 24 weeks.

Reporting group title	VX- 509 150 mg qd - Before Escape
-----------------------	-----------------------------------

Reporting group description:

VX-509 150 mg qd up to 24 weeks.

Reporting group title	VX-509 200 mg qd - Before Escape
-----------------------	----------------------------------

Reporting group description:

VX-509 200 mg qd up to 24 weeks.

Reporting group title	VX-509 100 mg bid - Before Escape
-----------------------	-----------------------------------

Reporting group description:

VX-509 100 mg bid up to 24 weeks.

Reporting group title	VX-509 150 mg qd - After Escape
-----------------------	---------------------------------

Reporting group description:

VX-509 150 mg qd up to 24 weeks.

Reporting group title	VX-509 200 mg qd - After Escape
-----------------------	---------------------------------

Reporting group description:

VX-509 200 mg qd up to 24 weeks.

Reporting group title	VX-509 150 mg qd - OLE
-----------------------	------------------------

Reporting group description:

VX-509 150 mg qd up to 104 weeks.

Reporting group title	VX-509 200 mg qd - OLE
-----------------------	------------------------

Reporting group description:

VX-509 200 mg qd up to 104 weeks.

Serious adverse events	Placebo - Before Escape	VX-509 100 mg qd - Before Escape	VX- 509 150 mg qd - Before Escape
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 71 (5.63%)	3 / 71 (4.23%)	6 / 72 (8.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Lung neoplasm			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Umbilical hernia repair			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenomyosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Pulmonary embolism			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
C-reactive protein increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Spinal compression fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			



Cerebral infarction			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo CNS origin			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic intolerance			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Stomatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cholelithiasis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Panniculitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			

subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	VX-509 200 mg qd - Before Escape	VX-509 100 mg bid - Before Escape	VX-509 150 mg qd - After Escape
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 72 (6.94%)	7 / 72 (9.72%)	1 / 29 (3.45%)
number of deaths (all causes)	1	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Umbilical hernia repair			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenomyosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
C-reactive protein increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Spinal compression fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
Acute myocardial infarction			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Angina unstable			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Angina pectoris			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo CNS origin			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic intolerance			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			



Neutropenia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Stomatitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Intestinal obstruction			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Panniculitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Bronchitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 72 (2.78%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	VX-509 200 mg qd - After Escape	VX-509 150 mg qd - OLE	VX-509 200 mg qd - OLE
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 64 (7.81%)	6 / 47 (12.77%)	22 / 218 (10.09%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Umbilical hernia repair			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenomyosis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
C-reactive protein increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Spinal compression fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac failure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo CNS origin			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Orthostatic intolerance			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			



Chorioretinitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Stomatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Panniculitis			

subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	3 / 218 (1.38%)
occurrences causally related to treatment / all	0 / 0	2 / 2	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastroenteritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo - Before Escape	VX-509 100 mg qd - Before Escape	VX- 509 150 mg qd - Before Escape
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 71 (40.85%)	36 / 71 (50.70%)	43 / 72 (59.72%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign breast neoplasm			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Benign lymph node neoplasm			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Bowen's disease			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Lung neoplasm			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Thyroid neoplasm			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2
Hypotension			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Hot flush			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Blood pressure fluctuation			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Haemorrhagic vasculitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Thrombosis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Flushing			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Phlebitis superficial			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	7
Pyrexia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Asthenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hunger			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Spinal pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Inflammation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Contrast media allergy			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Hypersensitivity			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Seasonal allergy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Menstruation irregular			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Prostatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vaginal prolapse			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal burning sensation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Ovarian cyst			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Adenomyosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Amenorrhoea			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Menopausal symptoms			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vaginal inflammation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	3 / 71 (4.23%)	0 / 71 (0.00%)	5 / 72 (6.94%)
occurrences (all)	3	0	5
Oropharyngeal pain			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	2 / 72 (2.78%)
occurrences (all)	1	1	2
Epistaxis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	0 / 72 (0.00%)
occurrences (all)	0	2	0
Nasal congestion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Pulmonary fibrosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0



Pulmonary embolism subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 71 (1.41%) 2	1 / 72 (1.39%) 1
Anxiety subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Depression subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Abnormal dreams subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 71 (1.41%) 1	0 / 72 (0.00%) 0
Nervousness subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Tension subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Depressed mood subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Initial insomnia subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Major depression subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Investigations			
Hepatic enzyme increased subjects affected / exposed occurrences (all)	2 / 71 (2.82%) 2	0 / 71 (0.00%) 0	2 / 72 (2.78%) 4
Alanine aminotransferase increased			

subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	1	0	3
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	3 / 72 (4.17%)
occurrences (all)	0	0	3
Transaminases increased			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	1	1	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cardiac murmur			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Blood pressure increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	2	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Human chorionic gonadotropin increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Liver function test abnormal			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Neutrophil count increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	2
Platelet count increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Red blood cell sedimentation rate increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
White blood cell count increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Blood cholesterol increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Candida test positive			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Chest X-ray abnormal			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Blood prolactin increased subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Lipids increased subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	2 / 71 (2.82%) 2	2 / 72 (2.78%) 4
Contusion subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 71 (1.41%) 1	2 / 72 (2.78%) 3
Ligament sprain subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Animal bite subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Limb injury subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Bone fissure subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 71 (1.41%) 2	0 / 72 (0.00%) 0
Excoriation			

subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Foot fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Laceration			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Skeletal injury			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	2
Tooth fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Pubis fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Ankle fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Meniscus lesion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Muscle strain			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Upper limb fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vaccination complication			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block first degree			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Left ventricular hypertrophy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Angina pectoris			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Atrial fibrillation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Bundle branch block left			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cardiac failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Mitral valve incompetence			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Supraventricular extrasystoles			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Thrombophlebitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Conduction disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Myocardial ischaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 71 (1.41%)	6 / 71 (8.45%)	7 / 72 (9.72%)
occurrences (all)	3	7	17
Dizziness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2
Dysgeusia			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	2	1	0
Somnolence			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Facial nerve disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Poor quality sleep			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Radicular pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Sleep paralysis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Polyneuropathy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cluster headache			



subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hypotonia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Mental impairment			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Hypochromic anaemia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Leukopenia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Neutropenia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Thrombocytopenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Lymphopenia subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Anaemia megaloblastic subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Eye disorders			
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 71 (1.41%) 1	1 / 72 (1.39%) 1
Dry eye subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Conjunctival ulcer subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Glaucoma subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Iritis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Blepharospasm			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cataract subcapsular			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	5 / 71 (7.04%)	6 / 71 (8.45%)	4 / 72 (5.56%)
occurrences (all)	7	9	4
Nausea			
subjects affected / exposed	4 / 71 (5.63%)	2 / 71 (2.82%)	3 / 72 (4.17%)
occurrences (all)	4	2	6
Abdominal pain upper			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	3 / 72 (4.17%)
occurrences (all)	1	2	3
Dyspepsia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	1	1	1
Vomiting			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	3 / 72 (4.17%)
occurrences (all)	1	0	3
Gastritis			
subjects affected / exposed	1 / 71 (1.41%)	2 / 71 (2.82%)	3 / 72 (4.17%)
occurrences (all)	1	2	3
Abdominal pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Abdominal discomfort			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2

Constipation			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Abdominal pain lower			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Glossodynia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	1	1	0
Toothache			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Aphthous stomatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Food poisoning			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Irritable bowel syndrome			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1

Peptic ulcer			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Tongue ulceration			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Colitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Liver disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Cholelithiasis			

subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	3 / 72 (4.17%)
occurrences (all)	0	0	3
Rash			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Alopecia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Dermatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Nail disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Onychoclasia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Pityriasis rosea			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Rash papular			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0

Skin ulcer			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Swelling face			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Actinic keratosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Subcutaneous nodule			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Renal and urinary disorders			
Leukocyturia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Dysuria			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Hypertonic bladder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Renal colic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Renal cyst			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	2 / 72 (2.78%)
occurrences (all)	0	2	2
Myalgia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Rheumatoid arthritis			
subjects affected / exposed	3 / 71 (4.23%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	3	0	0
Rheumatoid nodule			



subjects affected / exposed	2 / 71 (2.82%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	2	1	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Neck pain			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	0 / 72 (0.00%)
occurrences (all)	0	2	0
Arthralgia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Exostosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Nodal osteoarthritis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	2	0
Osteoarthritis			

subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Osteopenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Tendonitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Sjogren's syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Foot deformity			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Spinal column stenosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Joint instability			

subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Metatarsalgia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Osteochondrosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Spondylolisthesis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	2 / 71 (2.82%)	3 / 71 (4.23%)	1 / 72 (1.39%)
occurrences (all)	2	7	1
Upper respiratory tract infection			
subjects affected / exposed	2 / 71 (2.82%)	3 / 71 (4.23%)	1 / 72 (1.39%)
occurrences (all)	2	3	1
Bronchitis			
subjects affected / exposed	2 / 71 (2.82%)	2 / 71 (2.82%)	3 / 72 (4.17%)
occurrences (all)	3	2	3
Gastroenteritis			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	4 / 72 (5.56%)
occurrences (all)	1	3	5
Sinusitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1

Urinary tract infection			
subjects affected / exposed	0 / 71 (0.00%)	5 / 71 (7.04%)	1 / 72 (1.39%)
occurrences (all)	0	5	1
Pharyngitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	4 / 72 (5.56%)
occurrences (all)	1	0	4
Cystitis			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	0 / 72 (0.00%)
occurrences (all)	0	2	0
Herpes zoster			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	1 / 72 (1.39%)
occurrences (all)	0	2	1
Rhinitis			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	1 / 72 (1.39%)
occurrences (all)	0	2	1
Gastroenteritis viral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2
Influenza			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	1	0	2
Respiratory tract infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Herpes simplex			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	0	1	1
Vaginal infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	1	0	1

Breast infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Bronchopneumonia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Dental fistula			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Gastritis viral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Genital herpes			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Laryngitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Nail bed infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Oral fungal infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Oral herpes			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Post procedural infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Salmonellosis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Subcutaneous abscess subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Tonsillitis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Tooth abscess subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Tooth infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	1 / 72 (1.39%) 1
Acute sinusitis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Helicobacter infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 71 (0.00%) 0	0 / 72 (0.00%) 0

Mycotoxycosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Post procedural cellulitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Acute tonsillitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Borrelia infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Bronchitis viral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Tinea pedis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

Tracheitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	1 / 71 (1.41%)	3 / 71 (4.23%)	5 / 72 (6.94%)
occurrences (all)	1	3	5
Hyperlipidaemia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 71 (1.41%)	1 / 72 (1.39%)
occurrences (all)	1	1	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 71 (0.00%)	2 / 71 (2.82%)	3 / 72 (4.17%)
occurrences (all)	0	2	3
Dyslipidaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	2 / 72 (2.78%)
occurrences (all)	0	0	2
Dehydration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Diabetes mellitus			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	1 / 72 (1.39%)
occurrences (all)	0	0	1
Increased appetite			
subjects affected / exposed	0 / 71 (0.00%)	1 / 71 (1.41%)	0 / 72 (0.00%)
occurrences (all)	0	1	0
Gout			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			



subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 71 (0.00%)	0 / 71 (0.00%)	0 / 72 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	<b>VX-509 200 mg qd - Before Escape</b>	<b>VX-509 100 mg bid - Before Escape</b>	<b>VX-509 150 mg qd - After Escape</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 72 (65.28%)	41 / 72 (56.94%)	11 / 29 (37.93%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign breast neoplasm			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Benign lymph node neoplasm			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Bowen's disease			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lung neoplasm			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thyroid neoplasm			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 72 (6.94%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	5	1	0
Hypotension			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Hot flush			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Blood pressure fluctuation			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Haemorrhagic vasculitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Thrombosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Phlebitis superficial			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 72 (4.17%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	4	1	0
Malaise			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Hunger			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Early satiety			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Inflammation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Contrast media allergy			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypersensitivity			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Seasonal allergy subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Reproductive system and breast disorders			
Breast mass subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Menstruation irregular subjects affected / exposed occurrences (all)	1 / 72 (1.39%) 1	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	1 / 72 (1.39%) 1	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Vaginal prolapse subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Vulvovaginal burning sensation subjects affected / exposed occurrences (all)	1 / 72 (1.39%) 1	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Ovarian cyst subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Adenomyosis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Amenorrhoea subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Menopausal symptoms subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Vaginal inflammation			

subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 72 (5.56%)	3 / 72 (4.17%)	0 / 29 (0.00%)
occurrences (all)	4	3	0
Oropharyngeal pain			
subjects affected / exposed	2 / 72 (2.78%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	2	2	0
Epistaxis			
subjects affected / exposed	1 / 72 (1.39%)	3 / 72 (4.17%)	0 / 29 (0.00%)
occurrences (all)	1	4	0
Dyspnoea			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Pulmonary fibrosis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Abnormal dreams			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nervousness			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tension			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Depressed mood			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Initial insomnia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Major depression			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Investigations			
Hepatic enzyme increased			
subjects affected / exposed	5 / 72 (6.94%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	9	2	0
Alanine aminotransferase increased			
subjects affected / exposed	5 / 72 (6.94%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	5	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 72 (4.17%)	3 / 72 (4.17%)	0 / 29 (0.00%)
occurrences (all)	3	3	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 72 (2.78%)	4 / 72 (5.56%)	0 / 29 (0.00%)
occurrences (all)	2	4	0
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 72 (5.56%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	4	1	0
Blood triglycerides increased			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Transaminases increased			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 72 (2.78%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	2	1	0
Cardiac murmur			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Blood pressure increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Human chorionic gonadotropin increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Liver function test abnormal			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Lymphocyte count increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Red blood cell sedimentation rate increased			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Low density lipoprotein increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Candida test positive			



subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Chest X-ray abnormal			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood prolactin increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lipids increased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			
subjects affected / exposed	1 / 72 (1.39%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	1	2	0
Animal bite			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Limb injury			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Bone fissure			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Excoriation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Laceration			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Post-traumatic pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skeletal injury			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pubis fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ankle fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Meniscus lesion			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Upper limb fracture			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vaccination complication			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	1 / 72 (1.39%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	1	2	0
Atrioventricular block first degree			
subjects affected / exposed	0 / 72 (0.00%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Left ventricular hypertrophy			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
Palpitations			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Sinus bradycardia			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	1	0

Ventricular extrasystoles			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Angina pectoris			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Atrial fibrillation			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Bradycardia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Bundle branch block left			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Cardiac failure			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mitral valve incompetence			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Supraventricular extrasystoles			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Thrombophlebitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Conduction disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Myocardial ischaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			

subjects affected / exposed	6 / 72 (8.33%)	6 / 72 (8.33%)	0 / 29 (0.00%)
occurrences (all)	21	6	0
Dizziness			
subjects affected / exposed	2 / 72 (2.78%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	2	1	0
Dysgeusia			
subjects affected / exposed	2 / 72 (2.78%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	2	2	0
Migraine			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Facial nerve disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Paraesthesia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Poor quality sleep			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Radicular pain			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Sleep paralysis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Tension headache			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Polyneuropathy			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Carpal tunnel syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cluster headache			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypotonia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mental impairment			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Hypochromic anaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Neutropenia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Anaemia megaloblastic			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
Tinnitus			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
Vertigo			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	2	1	0
Eye disorders			
Conjunctivitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Dry eye			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Conjunctival ulcer			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Glaucoma			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Iritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Blepharospasm			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cataract subcapsular			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 72 (1.39%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	1	2	0
Nausea			
subjects affected / exposed	2 / 72 (2.78%)	3 / 72 (4.17%)	1 / 29 (3.45%)
occurrences (all)	8	3	1
Abdominal pain upper			
subjects affected / exposed	2 / 72 (2.78%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	2	1	0
Dyspepsia			
subjects affected / exposed	2 / 72 (2.78%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	2	2	0
Vomiting			
subjects affected / exposed	3 / 72 (4.17%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	6	0	0
Gastritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0



Abdominal pain			
subjects affected / exposed	2 / 72 (2.78%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	3	1	0
Abdominal discomfort			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Abdominal pain lower			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dry mouth			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	2 / 72 (2.78%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Abdominal distension			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Aphthous stomatitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Irritable bowel syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Peptic ulcer			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Tongue ulceration			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Liver disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Cholelithiasis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	2 / 72 (2.78%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Acne			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Ecchymosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Pityriasis rosea			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0

Pruritus			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Actinic keratosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Subcutaneous nodule subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Renal and urinary disorders			
Leukocyturia subjects affected / exposed occurrences (all)	2 / 72 (2.78%) 2	1 / 72 (1.39%) 2	1 / 29 (3.45%) 1
Dysuria subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	1 / 29 (3.45%) 1
Hypertonic bladder subjects affected / exposed occurrences (all)	1 / 72 (1.39%) 1	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Renal colic subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Renal cyst subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	2 / 72 (2.78%) 2	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Myalgia			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Rheumatoid arthritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rheumatoid nodule			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 72 (0.00%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Muscle spasms			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Bursitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Exostosis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Limb discomfort			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Lumbar spinal stenosis			

subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Nodal osteoarthritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Osteopenia			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Osteoporosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Sjogren's syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Foot deformity			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Spinal column stenosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Arthritis			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Joint instability			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Metatarsalgia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Osteochondrosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Spondylolisthesis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 72 (5.56%)	3 / 72 (4.17%)	1 / 29 (3.45%)
occurrences (all)	4	4	1
Upper respiratory tract infection			
subjects affected / exposed	3 / 72 (4.17%)	3 / 72 (4.17%)	1 / 29 (3.45%)
occurrences (all)	3	3	1
Bronchitis			
subjects affected / exposed	4 / 72 (5.56%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1



Gastroenteritis			
subjects affected / exposed	1 / 72 (1.39%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	1	1	0
Sinusitis			
subjects affected / exposed	3 / 72 (4.17%)	2 / 72 (2.78%)	0 / 29 (0.00%)
occurrences (all)	3	3	0
Urinary tract infection			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Cystitis			
subjects affected / exposed	2 / 72 (2.78%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	2	1	0
Herpes zoster			
subjects affected / exposed	2 / 72 (2.78%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Rhinitis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis viral			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 72 (2.78%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Herpes simplex			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0

Viral infection			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	1 / 29 (3.45%)
occurrences (all)	0	1	1
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Breast infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Bronchopneumonia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Dental fistula			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Furuncle			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Gastritis viral			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Genital herpes			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Nail bed infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Oral fungal infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Oral herpes			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Otitis media			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	2	0	0
Post procedural infection			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Salmonellosis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 72 (1.39%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Soft tissue infection			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	1 / 72 (1.39%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Acute sinusitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Helicobacter infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Mycotoxycosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Post procedural cellulitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Acute tonsillitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Borrelia infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Bronchitis viral			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Staphylococcal infection subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Tinea pedis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Tracheitis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Metabolism and nutrition disorders			
Hypercholesterolaemia subjects affected / exposed occurrences (all)	3 / 72 (4.17%) 3	4 / 72 (5.56%) 4	1 / 29 (3.45%) 1
Hyperlipidaemia subjects affected / exposed occurrences (all)	2 / 72 (2.78%) 2	2 / 72 (2.78%) 2	1 / 29 (3.45%) 1
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Dyslipidaemia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 72 (1.39%) 1	0 / 29 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Diabetes mellitus subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 72 (0.00%) 0	0 / 29 (0.00%) 0
Gout			

subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 72 (0.00%)	0 / 72 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	VX-509 200 mg qd - After Escape	VX-509 150 mg qd - OLE	VX-509 200 mg qd - OLE
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 64 (56.25%)	28 / 47 (59.57%)	118 / 218 (54.13%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign breast neoplasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Benign lymph node neoplasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Bowen's disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Lung neoplasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Squamous cell carcinoma			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Thyroid neoplasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Vascular disorders			

Hypertension			
subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	8 / 218 (3.67%)
occurrences (all)	0	2	9
Hypotension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Blood pressure fluctuation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Haemorrhagic vasculitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Phlebitis superficial			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Orthostatic hypotension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Pyrexia			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	5 / 218 (2.29%)
occurrences (all)	1	1	5
Chest discomfort			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Hunger			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	1	1	0
Spinal pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Early satiety			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Chest pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Inflammation			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			



Contrast media allergy subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	2 / 218 (0.92%) 2
Reproductive system and breast disorders			
Breast mass subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Menstruation irregular subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Vaginal prolapse subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Vulvovaginal burning sensation subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Ovarian cyst subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	1 / 218 (0.46%) 1
Adenomyosis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	0 / 218 (0.00%) 0
Amenorrhoea			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Menopausal symptoms			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Vaginal inflammation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 64 (3.13%)	0 / 47 (0.00%)	9 / 218 (4.13%)
occurrences (all)	2	0	10
Oropharyngeal pain			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	1	1	2
Epistaxis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Nasal congestion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	2
Pulmonary fibrosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Sinus congestion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Lung infiltration			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Anxiety			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Abnormal dreams			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Nervousness			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Tension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Depressed mood			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1

Initial insomnia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Major depression subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Investigations			
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	2 / 218 (0.92%) 2
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	2 / 47 (4.26%) 2	5 / 218 (2.29%) 6
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 3	3 / 218 (1.38%) 3
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	4 / 218 (1.83%) 5
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	1 / 47 (2.13%) 1	4 / 218 (1.83%) 4
Blood triglycerides increased subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Transaminases increased subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	3 / 218 (1.38%) 3
Cardiac murmur subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0

Blood pressure increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Human chorionic gonadotropin increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Liver function test abnormal			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Lymphocyte count increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Red blood cell sedimentation rate increased			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	2	1
Weight decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
White blood cell count decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			

subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	1	1	2
Low density lipoprotein increased			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	3 / 218 (1.38%)
occurrences (all)	1	1	4
Candida test positive			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Chest X-ray abnormal			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Blood prolactin increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Body temperature increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Lipids increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	4 / 218 (1.83%)
occurrences (all)	0	2	4
Contusion			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	1	1	3
Ligament sprain			

subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	2 / 218 (0.92%)
occurrences (all)	0	2	2
Animal bite			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Bone fissure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Excoriation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Foot fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Laceration			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Post-traumatic pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Skeletal injury			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	1	1	0
Pubis fracture			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Humerus fracture			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Rib fracture			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Ankle fracture			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Arthropod bite			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Meniscus lesion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Muscle strain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Road traffic accident			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Spinal compression fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Upper limb fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Vaccination complication			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cardiac disorders			
Tachycardia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Atrioventricular block first degree			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	3 / 218 (1.38%)
occurrences (all)	0	0	4
Left ventricular hypertrophy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0



Palpitations			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Sinus bradycardia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	5 / 218 (2.29%)
occurrences (all)	0	0	5
Ventricular extrasystoles			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Angina pectoris			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Bradycardia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Bundle branch block left			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Cardiac failure			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Mitral valve incompetence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Thrombophlebitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Conduction disorder			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

Myocardial ischaemia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	2 / 64 (3.13%) 2	0 / 47 (0.00%) 0	6 / 218 (2.75%) 6
Dizziness subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Dysgeusia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	3 / 218 (1.38%) 4
Somnolence subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Facial nerve disorder subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Poor quality sleep subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Radicular pain subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Sleep paralysis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Polyneuropathy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cluster headache			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hypotonia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Mental impairment			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	2
Syncope			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	2 / 218 (0.92%)
occurrences (all)	0	2	2

Hypochromic anaemia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	0 / 218 (0.00%) 0
Lymphopenia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	1 / 218 (0.46%) 1
Anaemia megaloblastic subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Tinnitus subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0
Eye disorders Conjunctivitis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	0 / 218 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Conjunctivitis allergic			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Conjunctival ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	2
Glaucoma			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Iritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cataract			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Cataract subcapsular			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Keratitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	2 / 218 (0.92%)
occurrences (all)	0	3	3
Nausea			
subjects affected / exposed	2 / 64 (3.13%)	1 / 47 (2.13%)	3 / 218 (1.38%)
occurrences (all)	2	1	5
Abdominal pain upper			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	1	1	2
Dyspepsia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

Vomiting			
subjects affected / exposed	1 / 64 (1.56%)	2 / 47 (4.26%)	1 / 218 (0.46%)
occurrences (all)	1	2	1
Gastritis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	2
Abdominal pain			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Abdominal discomfort			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Abdominal pain lower			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Aphthous stomatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0

Food poisoning			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	0	1	2
Irritable bowel syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Peptic ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tongue ulceration			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Cheilitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hypoaesthesia oral			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Pancreatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Periodontitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hyperbilirubinaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Liver disorder			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Cholelithiasis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Rash			
subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	3 / 218 (1.38%)
occurrences (all)	0	2	3
Acne			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Dermatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Nail disorder			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			



subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Pityriasis rosea			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Swelling face			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Dermatitis allergic			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	1	0	2
Dermatitis contact			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Dry skin			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Actinic keratosis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	3
Hyperkeratosis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Psoriasis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Subcutaneous nodule			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Leukocyturia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	5
Dysuria			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hypertonic bladder			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Renal colic			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Haematuria			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Nocturia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Renal cyst			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Urinary incontinence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	6 / 218 (2.75%)
occurrences (all)	0	0	6
Myalgia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Rheumatoid arthritis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	6 / 218 (2.75%)
occurrences (all)	0	1	6
Rheumatoid nodule			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Musculoskeletal chest pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	0	1	2
Neck pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	2
Arthralgia			
subjects affected / exposed	1 / 64 (1.56%)	2 / 47 (4.26%)	3 / 218 (1.38%)
occurrences (all)	1	2	3
Bursitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	1	0	2
Exostosis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Nodal osteoarthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	3 / 218 (1.38%)
occurrences (all)	0	0	3
Osteopenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Sjogren's syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 64 (0.00%)	2 / 47 (4.26%)	1 / 218 (0.46%)
occurrences (all)	0	2	1
Foot deformity			

subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Spinal column stenosis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	0	1	1
Arthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Joint instability			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Metatarsalgia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Osteochondrosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Spinal osteoarthritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Spondylolisthesis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 64 (1.56%)	2 / 47 (4.26%)	12 / 218 (5.50%)
occurrences (all)	1	3	19

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	2 / 47 (4.26%) 2	13 / 218 (5.96%) 15
Bronchitis subjects affected / exposed occurrences (all)	3 / 64 (4.69%) 3	0 / 47 (0.00%) 0	12 / 218 (5.50%) 14
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 47 (0.00%) 0	2 / 218 (0.92%) 2
Sinusitis subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	5 / 218 (2.29%) 5
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 64 (4.69%) 3	1 / 47 (2.13%) 1	5 / 218 (2.29%) 6
Pharyngitis subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	2 / 47 (4.26%) 2	1 / 218 (0.46%) 1
Cystitis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	0 / 218 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	8 / 218 (3.67%) 8
Rhinitis subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	1 / 47 (2.13%) 1	1 / 218 (0.46%) 2
Gastroenteritis viral subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	1 / 218 (0.46%) 1
Influenza subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 47 (2.13%) 1	2 / 218 (0.92%) 2
Respiratory tract infection subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 47 (0.00%) 0	0 / 218 (0.00%) 0

Herpes simplex			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	0	0	2
Vaginal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	3 / 218 (1.38%)
occurrences (all)	1	0	3
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	5
Breast infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Bronchopneumonia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Dental fistula			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Gastritis viral			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Genital herpes			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Nail bed infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0

Oral candidiasis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	0	1	2
Oral fungal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Otitis media			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Post procedural infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Salmonellosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Soft tissue infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	1 / 64 (1.56%)	1 / 47 (2.13%)	1 / 218 (0.46%)
occurrences (all)	1	1	1



Acute sinusitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal viral infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Helicobacter infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Lower respiratory tract infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	2	0	0
Mycotoxycosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Post procedural cellulitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	2 / 218 (0.92%)
occurrences (all)	0	1	2
Acute tonsillitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Borrelia infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Bronchitis viral			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

Onychomycosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Rash pustular			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	3
Staphylococcal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Tinea pedis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Tracheitis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 64 (0.00%)	1 / 47 (2.13%)	0 / 218 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	3 / 64 (4.69%)	3 / 47 (6.38%)	10 / 218 (4.59%)
occurrences (all)	3	3	10
Hyperlipidaemia			
subjects affected / exposed	2 / 64 (3.13%)	0 / 47 (0.00%)	2 / 218 (0.92%)
occurrences (all)	2	0	2
Hypertriglyceridaemia			
subjects affected / exposed	1 / 64 (1.56%)	3 / 47 (6.38%)	4 / 218 (1.83%)
occurrences (all)	1	3	4
Dyslipidaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	5 / 218 (2.29%)
occurrences (all)	1	0	5
Dehydration			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	0 / 218 (0.00%)
occurrences (all)	0	0	0
Diabetes mellitus			

subjects affected / exposed	1 / 64 (1.56%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	1	0	1
Increased appetite			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Gout			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 64 (0.00%)	0 / 47 (0.00%)	1 / 218 (0.46%)
occurrences (all)	0	0	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 January 2012	Updated baseline characteristics and secondary endpoints.
03 February 2012	Updated baseline characteristics and secondary endpoints.
27 September 2012	Clarified planned analysis.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated early by the sponsor due to a decision to modify the drug development plan. The early termination was not due to a safety signal or lack of efficacy.

Notes: